Source comparison
Hexarelin vs Ipamorelin: Research Applications Comparison
The following table summarizes the critical differences between hexarelin and ipamorelin across parameters that determine research suitability. Use this to match peptide selection to your study's primary endpoints and acceptable confounders. GHSR-1a Selectivit
This comparison does not assign a generated winner or score.
- The following table summarizes the critical differences between hexarelin and ipamorelin across parameters that determine research suitability. Use this to match peptide selection to your study's primary endpoints and acceptable confounders.
- GHSR-1a Selectivity
- Moderate. Binds GHSR-1a, GHSR-1b, CD36 receptors
- High. >95% selective for GHSR-1a only
- Ipamorelin produces cleaner data in studies where off-target receptor activity introduces confounders
- Peak GH Output
- 12–18 ng/mL at 200 mcg/kg (rodent models)
- 8–12 ng/mL at equivalent dose
- Hexarelin produces 30–40% higher GH per dose but with hormonal trade-offs
- Cortisol Response
- +30–50% within 60 min at therapeutic doses
- No measurable increase at any tested dose
- Cortisol elevation disqualifies hexarelin from metabolic and insulin sensitivity studies
- Prolactin Response
- +20–40% in 40–50% of administrations
- No measurable increase
- Hexarelin unsuitable for neuroendocrine or reproductive research where prolactin is a variable
- Receptor Desensitization
- 40–60% decline in GH response after 14 days daily use
- <15% decline after 28 days daily use
- Ipamorelin maintains consistent GH stimulus in chronic studies; hexarelin requires cycling
- Half-Life
- 70–90 minutes; duration of action 4–6 hours
- 90–120 minutes; effective window 3–4 hours
- Similar pharmacokinetics; hexarelin's longer receptor occupancy suits once-daily protocols
- Optimal Study Duration
- Acute studies (7–14 days) to limit desensitization
- Chronic studies (21+ days) requiring hormonal stability
- Hexarelin for short-term high-output; ipamorelin for sustained moderate elevation